The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 21, 2007

Filed:

Jul. 23, 2001
Applicants:

Anuschirwan Peyman, Kelkheim, DE;

David Will, Kriftel, DE;

Thomas R Gadek, Oakland, CA (US);

Robert Mcdowell, San Francisco, CA (US);

Jean Francois Gourvest, Claye Souilly, FR;

Jean-marie Ruxer, Issy les Moulineaux, FR;

Jochen Knolle, Frankfurt am Main, DE;

Inventors:

Anuschirwan Peyman, Kelkheim, DE;

David Will, Kriftel, DE;

Thomas R Gadek, Oakland, CA (US);

Robert McDowell, San Francisco, CA (US);

Jean Francois Gourvest, Claye Souilly, FR;

Jean-Marie Ruxer, Issy les Moulineaux, FR;

Jochen Knolle, Frankfurt am Main, DE;

Assignees:

Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, DE;

Genentech Inc., South San Francisco, CA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 473/16 (2006.01); C07D 473/24 (2006.01); C07D 473/28 (2006.01); C07D 473/32 (2006.01); C07D 473/34 (2006.01); C07D 473/36 (2006.01); C07D 473/40 (2006.01); A61K 31/437 (2006.01); A61K 31/519 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention relates to acylguanidino derivatives of formula (I), in which R, R, R, A, B, X, Y and n have the meanings indicated in claim, their physiologically tolerable salts and their prodrugs. The compounds of the formula (I) are valuable pharmaceutically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and bone resorption by osteoclasts. This renders them suitable, for example, for the therapy and prophylaxis of illness which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth muscles. The invention furthermore relates to processes for the preparation of compounds of the formula (I), their use, in particular as pharmaceutical active ingredients, and pharmaceutical compositions comprising them


Find Patent Forward Citations

Loading…